HERTHENA-Breast04 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer Previously Treated with Endocrine Therapy The ...
X4 Pharmaceuticals announced the acceptance of two abstracts for presentation at the upcoming European Hematology Association Congress regarding the positive results from their Phase 2 trial of ...
lidERA Breast Cancer is a phase III, randomized, open-label, multicentre study evaluating the efficacy and safety of adjuvant giredestrant versus standard-of-care endocrine therapy in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback